All
6 February 2024
STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture
Starfish Bioscience today announced that it has raised €900,000 from Seventure Partners, the world's leading investor in the microbiome field through its Health for Life...
5 December 2023
Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines
Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful...
31 October 2023
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
30 October 2023
Les Assises: Zurich Resilience Solutions announces the launch of “Quantification as a Service”, powered by Citalid
Julien Chamonal, Chief Revenue Officer at Citalid, and Vivien Bilquez, Principal Cyber Risk Engineer at Zurich Insurance, co-hosted a presentation titled Cyber Insurance:...
30 October 2023
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...
26 October 2023
Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.
Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...
26 October 2023
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host...
9 October 2023
CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris
A French company that develops and manufactures innovative cardiac assist devices, held the grand opening of its new facility on the banks of the Seine in Clichy, next to...